BofA raised the firm’s price target on AbbVie to $172 from $167 and keeps a Neutral rating on the shares. The firm said the ImmunoGen deal’s early closure has improved AbbVie’s near-term growth outlook, as it added Elahere sales earlier than expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABBV: